Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdiaVita and Glutathione in Chronic Kidney Disease
NCT07572890Phase 1Recruiting
- Sponsor
- Adia Med, LLC
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AdiaVita in chronic kidney disease (CKD) (3 arms), sponsored by Adia Med, LLC. Primary endpoints: Estimated Glomerular Filtration Rate at 6 months and Serum Creatinine at 6 months. Started May 2026; status: recruiting.
02
Drugs
AdiaVita
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07572890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572890.